Which weight loss drugs are actually safe?
By the evidence, the safest prescription weight loss drugs are the GLP-1 medications, semaglutide and tirzepatide. They are the only ones tested in large, multi-year trials, and semaglutide is the only weight loss drug shown to reduce heart attacks, strokes, and deaths. Phentermine/topiramate is effective and approved for long-term use, but it has no cardiovascular outcome trial and is off-limits in pregnancy and heart disease. Phentermine alone and phendimetrazine are older stimulants approved only for a few weeks of use; the long-term safety data simply do not exist. And no drug is safe in the abstract. Safe means the right drug matched to your labs, your blood pressure, and your history.
After two decades of practicing medicine, I have watched weight loss drugs go from a stimulant prescribed for three weeks to a class of medications that changes heart outcomes. Patients ask me which one is safe. The better question is which one is safe for you, and that is a lab-and-history question, not a Google question. Here is how the four options stack up.
Written by Dr. Ty Tallman, NMD, Integrative Medical Partners, Mesa, AZ. Updated September 22, 2026.
The four options, ranked by safety evidence
| Drug | FDA-approved for | Long-term safety data | Biggest caution |
|---|---|---|---|
| Semaglutide (GLP-1) | Chronic weight management | Strongest: multi-year trials plus a dedicated cardiovascular outcomes trial showing fewer heart attacks, strokes, and deaths | Nausea, vomiting, diarrhea; gallbladder disease; small heart rate increase |
| Tirzepatide (GLP-1/GIP) | Chronic weight management | Strong for weight and metabolic markers; its cardiovascular outcomes trial in obesity is still running | Highest rates of stomach side effects and stopping for side effects |
| Phentermine/topiramate ER | Chronic weight management | Moderate: 1 to 2 year trials, no cardiovascular outcomes trial | Birth defects (mandatory pregnancy testing), avoid in heart disease and uncontrolled blood pressure, irritability, insomnia, glaucoma |
| Phentermine alone | Short-term use only (up to 12 weeks) | Weak: observational studies only, reassuring but not proof | Raises heart rate and blood pressure; avoid in heart disease; long-term use is off-label |
| Phendimetrazine | Short-term use only (a few weeks) | Essentially none | Label warns of a 23-fold rise in pulmonary hypertension risk with use beyond 3 months; tolerance within weeks; Schedule III |
Why the GLP-1s sit at the top
Safety is not the absence of side effects. It is knowing what happens to people who take a drug for years. The GLP-1 class is the only weight loss category where we know. In the largest network analysis to date, covering 262 trials and roughly 100,000 people, semaglutide was the only drug associated with lower all-cause mortality (about 19% lower) and fewer heart attacks (about 28% fewer). Both semaglutide and tirzepatide cut heart failure risk roughly in half. That evidence comes from dedicated cardiovascular outcome trials such as SELECT, run in people who already had heart disease. No other weight loss drug has anything comparable.
Tirzepatide produces the most weight loss of any medication, but its own cardiovascular outcomes trial in obesity is still underway, and real-world comparisons against semaglutide cut both ways. That is exactly why the American College of Physicians named both drugs first-line in 2026: tirzepatide for weight, semaglutide for proven heart protection. The trade-off is stomach side effects. They are common, mostly temporary, and mostly manageable when dosing is adjusted early. The class also carries a gallbladder risk and a small heart rate increase that we monitor.
Phentermine/topiramate: effective, with hard limits
Phentermine/topiramate ER (brand name Qsymia) deserves credit. It is approved for long-term use, it ranks second only to semaglutide among the older drugs for weight loss in network analyses, and its trials showed blood pressure going down, not up, with a modest heart rate bump. Roughly two-thirds of people on the full dose lost at least 5% of body weight at one year. Where it falls short is what we do not know: there is no cardiovascular outcomes trial, and the one available network estimate showed no signal of heart benefit at all.
The limits are firm. Topiramate roughly doubles the risk of oral clefts with first-trimester exposure, so the drug carries a federal safety program requiring a negative pregnancy test before starting and monthly during treatment. High-quality evidence shows it more than triples irritability and increases sleep disturbance. It can trigger acute angle-closure glaucoma, kidney stones, and metabolic acidosis, and every major guideline says avoid it in heart disease or uncontrolled hypertension. For the right patient it works well. For the wrong patient it is the wrong drug.
Phentermine alone: the honest middle
Phentermine is the most prescribed weight loss drug in America, and it is approved for a few weeks to 12 weeks of use. Anything beyond that is off-label. That does not make it dangerous, but it does mean the reassurance comes from observational data rather than trials. A review of nearly 14,000 patient records found that people who stayed on phentermine past three months lost more weight without more cardiovascular events over three years. A smaller study of about 270 patients treated continuously for an average of seven years found no worsening of blood pressure or heart rate. The Endocrine Society and the AGA both support long-term use in adults without cardiovascular disease, though the AGA calls its recommendation conditional because the long-term data are low quality.
Two things keep phentermine out of the top tier. First, it is a stimulant, and the label warns of palpitations, tachycardia, and elevated blood pressure; it is contraindicated in coronary disease, arrhythmias, stroke history, heart failure, uncontrolled hypertension, hyperthyroidism, and glaucoma. Second, the valve and pulmonary hypertension warnings on its label come from the fenfluramine era of the 1990s, and no prospective long-term cardiovascular trial has ever been completed. One is finally running: the NIH-funded LEAP trial. Until it reports, anyone on phentermine long-term should be told plainly that the long-term cardiovascular risk is unknown, and should have blood pressure and heart rate checked at every visit.
Phendimetrazine: the one I would pass on for long-term use
Phendimetrazine is in the same stimulant family as phentermine, but it is a Schedule III controlled substance with more abuse potential, and its evidence base is thin. The available trials are small, twelve weeks long, and show weight loss on par with the other stimulants. No study met the bar for inclusion in the major systematic review of long-term obesity drugs, and the 2025 VA/DoD guideline found no qualifying long-term studies at all. Its label is blunt: in the case-control study cited there, use beyond three months was associated with a 23-fold increase in the risk of primary pulmonary hypertension, a rare but often fatal disease. Tolerance develops within weeks, and the label says to stop at that point rather than push the dose. When a patient needs medication for more than a few weeks, the guidelines and I agree: use something approved for chronic weight management instead.
What safe actually means
Every one of these drugs is unsafe for someone. A stimulant in a patient with uncontrolled blood pressure. Topiramate in a woman who could become pregnant. A GLP-1 in someone with a personal or family history of medullary thyroid cancer, or a history of pancreatitis. The safety question is never the drug in isolation; it is the drug in a specific body. That is why over-the-counter weight loss pills and imported compounded products are the least safe option of all: nobody checked. If you want to see what unregulated products can do, read our page on herbal supplements and liver injury.
How we choose in our office
No weight loss medication is prescribed in our office without labs first. The panel tells us about your blood sugar, your liver, your kidneys, your thyroid, and your lipids, which is the difference between guessing and knowing which drug fits. Blood pressure and heart rate are checked at every visit, and any patient with a cardiovascular history or uncontrolled blood pressure is steered away from the stimulants entirely. Women who could become pregnant are screened before topiramate is ever considered. Then every patient checks in every 30 days, and adjustments happen at those check-ins, based on how you feel and what your labs show, never on a calendar alone. Your plan is individualized and provided through our office.
Common questions
Is phentermine safe long term?
Observational data over three to seven years are reassuring in people without heart disease, and two major guidelines support long-term use in that group. But it is off-label beyond 12 weeks, and no prospective cardiovascular trial has been completed. Reassuring is not the same as proven.
Is Qsymia safer than Ozempic or Wegovy?
No. Semaglutide has proven heart protection and phentermine/topiramate has none. Qsymia has fewer stomach side effects, but it carries pregnancy, mood, sleep, and glaucoma risks that semaglutide does not.
What is the safest weight loss pill?
Among the pills, phentermine/topiramate ER has the best combination of long-term approval and effectiveness. Whether it is safe for you depends on your pregnancy potential, your heart, your eyes, and your mood history.
Can I take a weight loss drug if I have high blood pressure?
If it is uncontrolled, the stimulants are off the table. Controlled blood pressure changes the conversation, and the GLP-1 medications tend to lower blood pressure as weight comes off. This is a visit-and-labs decision.
Are over-the-counter weight loss pills safe?
They are unregulated, untested for weight loss in any serious trial, and a recurring cause of liver injury. Save your money for something that works.
Do I need labs before starting?
Yes, every time. Labs are how we rule a drug in or out for you specifically, and how we know later whether the weight you are losing is fat or muscle.
Related reading: how GLP-1s reduce cardiovascular risk, can GLP-1s cause vision loss, the truth about microdosing GLP-1s, and medical weight loss in Mesa, AZ.
Safe weight loss medication
Safe weight loss medication, managed by your physician with a check-in every 30 days.
GLP-1 plans $349/month · first month $449
Questions first? Text us. Ready? Book now. · 1910 S Stapley Dr #120, Mesa, AZ 85204
To Health and Wellness, Dr. Ty Tallman
References
- BMJ, 2026 — comparative effects of drugs for adults with overweight or obesity, network meta-analysis of 262 trials
- Annals of Internal Medicine, 2026 — American College of Physicians living guideline on pharmacologic treatment of overweight and obesity
- Nature Medicine, 2025 — efficacy and safety of pharmacological treatments for obesity in adults, meta-analysis
- EClinicalMedicine, 2025 — anti-obesity medications and cardiometabolic and psychological outcomes, meta-analysis
- Endocrine Practice, 2025 — AACE consensus algorithm for adults with obesity, 2025 update
- JAMA, 2024 — medications for obesity, a review
- JAMA, 2023 — obesity management in adults, a review
- Gastroenterology, 2022 — AGA clinical practice guideline on pharmacological interventions for adults with obesity
- Obesity, 2021 — phentermine/topiramate in adults with overweight or obesity, systematic review and meta-analysis
- JAMA, 2014 — long-term drug treatment for obesity, systematic and clinical review
- FDA prescribing information, 2025–2026 — phentermine, phendimetrazine tartrate, and phentermine/topiramate ER labels